Nucleic Acid Therapeutics is the leading journal in its field focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal examines many new approaches for using nucleic acids as therapeutic agents or in modifying nucleic acids for therapeutic purposes including: oligonucleotides, gene modification, aptamers, RNA nanoparticles, and ribozymes.
Nucleic Acid Therapeutics coverage includes:
RNAi: siRNAs, shRNAs, and miRNAs
Antisense applications; nucleoside and nucleotide analogs and modifications
Peptide nucleic acids
DNA-modified gene therapy
Nucleic acid-based nanoparticles
Ethical, legal, and regulatory issues
Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center and Annemieke Aartsma-Rus, PhD, Leiden University Medical Center; Executive Editor Graham C. Parker, PhD; and other leading investigators.
Audience: Molecular biologists, biochemists, DNA and cell biologists, and biopharmaceutical researchers, among others.